(Q36901533)

17 August 2017

1 reference

title

Introduction: organ involvement in the cardiometabolic syndrome (English)

1 reference

17 August 2017

Melvin R Hayden

1

1 reference

17 August 2017

Craig S Stump

series ordinal

2

1 reference

17 August 2017

James R Sowers

series ordinal

3

1 reference

17 August 2017

publication date

1 January 2006

1 reference

Journal of the cardiometabolic syndrome

17 August 2017

published in

1 reference

17 August 2017

volume

1

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

16-24

1 reference

Update on the cardiometabolic syndrome

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Oxidative stress and diabetic cardiomyopathy: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Diabetes, hypertension, and cardiovascular disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Non-alcoholic fatty liver: another feature of the metabolicsyndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Plaque Neovascularization Is Increased in Ruptured Atherosclerotic Lesions of Human Aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

The extracellular matrix on atherogenesis and diabetes-associated vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Natural history and histological classification of atherosclerotic lesions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

The accumulation of specific types of proteoglycans in eroded plaques: a role in coronary thrombosis in the absence of rupture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

New Insights Into Diabetic Polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Hypertension, angiotensin II, and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Insulin resistance, ADMA levels, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

The metabolic syndrome and chronic kidney disease in U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0197-3118.2006.05454.X

10.1111/J.0197-3118.2006.05454.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference